It was an honor to present, on behalf of the co-investigators, the planned OS results from FLAURA2 ph III at #WCLC25. These results confirm a shift in our first-line practice for our EGFRm pts, marking the first time a study has achieved a significant benefit mOS of 4Y. #EGFR

Dr. Jonathan Goldman presents the HARMONi data at #WCLC25. In EGFR NSCLC post TKI, adding ivonescimab (VEGF/PD1 bispecific) improves PFS (4.4 to 6.8m, HR 0.52). Numeric difference in OS in Western pts, but complicated analysis in heterogenous group. Improvement over MARIPOSA2?

#WCLC25 Presidential Superb FLAURA2 OS discussion by @danieltanmd, main questions: - combo may ⬆️likelihood of long-term response? - clinical/molec/ctDNA factors relevant - refinement needs complex integration of factors Extremely elegant slides, I plan to use 😃 @IASLC #LCSM

E4512: adjuvant crizotinib for resected stage II-III ALK+ NSCLC #DavidGerber. Insightful discussion by @JessicaJLinMD #WCLC25 💠Adjuvant crizotinib did not prolong median DFS 💠Biomarkers still critical for early-stage NSCLC given role of TKIs eg. osi (ADAURA) & alectinib (ALINA)

Awaited results of HARMONi trial evaluating ivonescimab, a PD1/VEGF bispecific presented by Dr. Jonathan Goldman presented @IASLC #WCLC25 🔹PFS HR 0.52 🔹OS immature How will this fit into a packed landscape of chemo, ADCs and amivantamab based therapy? It remains important to

Exciting #ARROS1 phase 1/2 trial results of #zidesamtinib in ROS+ mNSCLC #WCLC25 @alexdrilon 💠Active in heavily pretreated pts: ORR 44% after 1-4 prior ROS1 TKIs; 51% after 1 prior TKI (criz or entrect) 💠Responses after prior repotrectinib & taletrectinib; active against G2032R

Exciting final overall survival analysis of FLAURA2: osi + PT/pem vs osi alone for #EGFRm NSCLC #WCLC25 @dplanchard 💠⬆️OS with osi/CTx (median 47.5 mo) vs osi (37.6 mo) 💠Benefit despite median exposure to pem 8.3 mo & most pts in control arm receiving subsequent PT-based chemo

At NOSCM, @JuliaRotow presents provocative data supporting continuation of EGFR TKIs after progressive disease, so-called treatment beyond progression (TBP). I am increasingly a believer. Invariably there are residual sensitive clones which need to be controlled

🌓Yin&Yang Masterclass 2025 1st edition comes to an end. Huge thanks to all young and early-career investigators for stepping up, and to the stellar faculty for guiding them with passion and vision. Next stop: Paris 2026 🇨🇵 Stay tuned! #YinYang2025 @mihaela_aldea @BRicciutiMD

Enjoyed participating in the session on adjuvant #EGFR & #ALK TKI at Yin & Yang Lung Cancer Masterclass w/ @Tony_Calles & @MarianaBrandao0 w/ important debate on role of adjuvant chemo prior to TKI. Thanks to @mihaela_aldea @RobertoFerrara_ @BRicciutiMD for the chance to present!

Dynamic debate b/w @JuliaRotow & @BenjaminBesseMD on 1L combos vs 1L osi for #EGFR+ NSCLC 💠#FLAURA2 & #MARIPOSA more effective for most subgroups than osi alone: highly important for pts w/⬆️risk features 💠Significant tox of MARIPOSA: need for mitigation (subQ ami, COCOON ppx)

Fantastic debate b/w @JessicaJLinMD & @NarjustFlorezMD at Yin & Yang Lung Ca Masterclass: 1L lorlatinib vs 1L 2G TKIs for ALK+ mNSCLC 💠Median PFS >5yrs of 1L lorla. More limited 2L+ activity especially w/o secondary mut 💠More challenging tox of lorla: neurocog AE,⬆️wt, HLD, etc

Excited to be at the Yin & Yang Lung Cancer Masterclass organized by @mihaela_aldea @RobertoFerrara_ @BRicciutiMD. Innovative roundtable on clinical trial design + engaging & informative workshop/article discussions. Honored to be in Milan at the 1st Ed of this amazing conference

@SWaliany presented treatm options and sequences in ALK+ resected NSCLC. @Tony_Calles @MarianaBrandao0 fighting on the role of adjuvant chemo in oncogene+ NSCLC at #Yin&Yang Lung Cancer Masterclass 2025. Nice perspectives on the ideal ALINA trial @mihaela_aldea @BiagioRicciutMD

Datopotamab deruxtecan-dlnk receives accelerated FDA approval for treating EGFR-mutated non-small cell lung cancer. 📄 Full details ➡️ https://t.co/qNQJPyCOaq #FDAApproval #OncologyNews #NSCLC #AcceleratedApproval

Clinical case submissions are now open for the Yin & Yang Lung Cancer Masterclass! July 11-12, 2025 in Milan, Italy <40? Oncologist, surgeon, or rad onc? Submit by June 15! Submit a case on one of the topics: 1️⃣ Multimodal Rx (resectable/LA NSCLC) 2️⃣ Adjuvant EGFR/ALK+ NSCLC 3️⃣

Striking activity with ABBV-706 SEZ6 ADC in high grade neuroendocrine cancer (NECs) where active therapies are urgently needed. Thank you to the patients and their families. @alissajcooper #LCSM

Congratulations to Charlie Rudin & DeLLphi-304 investigators on this practice-changing trial for our patients with small cell lung cancer @MSKCancerCenter Tarlatamab in SCLC after Platinum-Based Chemotherapy | New England Journal of Medicine

💫 Rising star Dr. Catherine Meador with a clear and nuanced discussion of multiple practice changing talks in #SCLC. #ASCO25 @MassGeneralNews @MGHCancerCenter @MGHThoracicOnc

Telisotuzumab adizutecan (ABBV-400, Temab-A) in #EGFR NSCLC at #ASCO25. This is a cMET ADC like Teliso-V but with a topoisomerase 1 inhibitor. Safety notable for myelosuppression, 7% pneumonitis (1 fatal). RR 63%, DOR 9.8m, PFS 10.9m.